|View printer-friendly version|
|Medtronic Showcases Aortic Leadership in Innovation with Clinical Release and Pipeline at VEITH 2015|
New Aortic Data Demonstrates Medtronic's Commitment to Innovation
DUBLIN - November 16, 2015 - Medtronic plc (NYSE: MDT) today announced notable clinical studies and innovative technologies that will be presented at the annual VEITHsymposium, the world's premier conference for vascular surgeons specializing in the most current information and new developments in clinical practice and research. The conference is taking place in New York City from November 17-21, 2015.
"Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm (AAA) and descending thoracic disease, Endurant® and Valiant® product lines, have been proven in more than 280,000 patients globally," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease."
The VEITHsymposium will begin with a special session focusing on new developments in AAA and endovascular aneurysm repair (EVAR). This session will feature the highly anticipated four-year subset results on hostile neck anatomies from the ENGAGE Global Registry for Medtronic's Endurant AAA stent graft system. Hence J.M. Verhagen, M.D., Ph.D., Professor and Chief of Vascular Surgery, Erasmus University Medical Center in Rotterdam, the Netherlands, will present this real-world data on the opening day of VEITH. Additionally, four-year results from the full ENGAGE registry cohort will be presented on Saturday, November 21, 2015, by Marc R.H.M van Sambeek, M.D., Ph.D, Department of Vascular Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Medtronic's recently acquired EndoAnchor system will also be highlighted in nine presentations examining clinical applicability. The Heli-FX® EndoAnchor® system is an endovascular deployed anchor designed to attach a variety of aortic endografts to the native vessel wall.
Finally, several Medtronic products in clinical trials will be highlighted, such as the Endurant® Evo AAA stent graft system, as well as products for complex aortic disease, including:
Tuesday, November 17
Wednesday, November 18
Thursday, November 19
Details such as times, titles and locations are subject to change.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
About VEITH symposium
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.